Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Li, Quan Lin ^a   Gu, Fang Ming ^a   Wang, Zheng ^a   Jiang, Jia Hao ^a   Yao, Li Qing ^a   Tan, Chang Jun ^a   Huang, Xiao Yong ^a   Ke, Ai Wu ^a   Dai, Zhi ^a,b   Fan, Jia ^a,b   Zhou, Jian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Key Laboratory of Organ Transplantation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; RAPAMYCIN; SORAFENIB; SMALL INTERFERING RNA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

RATTUS;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84863240722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033379     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global Cancer Statistics. CA Cancer J Clin 61: 69-90.
2. Schwartz M, Roayaie S, Llovet J, (2005) How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 43: 584-589.
3. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135.
4. Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, et al. (2008) Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49: 78-87.
5. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, et al. (2008) Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14: 5124-5130.
6. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, et al. (2008) Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 248 (5): 857-862.
7. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, et al. (2010) Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 89 (2): 227-231.
8. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM, (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51 (4): 1237-1243.
9. Huang S, Houghton PJ, (2001) Mechanisms of resistance to rapamycins. Drug Resist Updat 4 (6): 378-391.
10. Kurmasheva RT, Huang S, Houghton PJ, (2006) Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95 (8): 955-960.
11. Jimenez RH, Boylan JM, Lee JS, Francesconi M, Castellani G, et al. (2009) Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One 4 (10): e7373.
12. Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, et al. (2011) Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 17 (34): 3922-3932.
13. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112 (8): 1223-1233.
14. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, et al. (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117 (3): 730-738.
15. Manning BD, (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167 (3): 399-403.
16. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118 (9): 3065-3074.
17. Liu J, Stevens PD, Gao T, (2011) mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem 286 (8): 6510-6520.
18. Schlessinger J, (2000) Cell signaling by receptor tyrosine kinases. Cell 103 (2): 211-225.
19. Jones AV, Cross NC, (2004) Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 61 (23): 2912-2923.
20. Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K, et al. (2001) Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. J Cell Sci 114 (Pt 8): 1533-1544.
21. Hackzell A, Uramoto H, Izumi H, Kohno K, Funa K, (2002) p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J Biol Chem 277 (42): 39769-39776.
22. Molander C, Hackzell A, Ohta M, Izumi H, Funa K, (2001) Sp1 is a key regulator of the PDGF beta-receptor transcription. Mol Biol Rep 28 (4): 223-233.
23. Shah OJ, Wang Z, Hunter T, (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14 (18): 1650-1656.
24. Carracedo A, Baselga J, Pandolfi PP, (2008) Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7 (24): 3805-3809.
25. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activation and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (19): 7099-7109.
26. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, et al. (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 13 (8B): 2673-2683.
27. Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, et al. (2011) Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10 (6): 1007-1017.
28. Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, et al. (2006) Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroentero 12 (19): 3114-3118.
29. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, et al. (2008) Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 40 (10): 3548-3553.
30. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, et al. (2010) Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 52 (5): 771-775.
31. Wang Y, Speeg KV, Washburn WK, Halff G, (2010) Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol 16 (43): 5518-5522.